Product image of Micofenolato De Mofetil Aurovitas (Mycophenolate Mofetil) supplied by GNH India

Micofenolato De Mofetil Aurovitas

Active Ingredient:
Mycophenolate Mofetil
Origin:
EU

Micofenolato De Mofetil Aurovitas (Mycophenolate Mofetil)

Mycophenolate Mofetil, the active ingredient in Micofenolato De Mofetil Aurovitas, is an immunosuppressant presented as an oral tablet for oral use. It is employed to prevent organ transplant rejection and to treat autoimmune conditions such as lupus nephritis, helping to control immune‑mediated damage.

GNH India supplies Micofenolato De Mofetil Aurovitas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Manufacturer / TM Owner

Generis Farmacêutica, S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Mycophenolate Mofetil is an antimetabolite immunosuppressant used in transplant and autoimmune disease management.
  • Kidney transplant: reduces the risk of acute graft rejection.
  • Liver transplant: supports long‑term graft survival.
  • Lupus nephritis: helps control renal inflammation and preserve kidney function.

How It Works

  • Mycophenolate Mofetil selectively inhibits inosine monophosphate dehydrogenase (IMPDH), a key enzyme in the de novo synthesis of guanosine nucleotides. By limiting guanosine availability, the drug suppresses proliferation of T‑ and B‑lymphocytes, which rely heavily on this pathway, thereby dampening the adaptive immune response that drives transplant rejection and autoimmune inflammation.

Side Effects

Mycophenolate Mofetil may cause a range of adverse reactions, from mild to severe.

Common Side Effects

  • Gastrointestinal upset: nausea, vomiting, diarrhea.
  • Hematologic changes: anemia, leukopenia, thrombocytopenia.
  • Infections: increased susceptibility to bacterial, viral and fungal infections.
  • Headache and fatigue.
  • Elevated liver enzymes.

Serious or Rare Side Effects

  • Severe neutropenia or agranulocytosis.
  • Opportunistic infections such as Pneumocystis jirovecii pneumonia.
  • Progressive multifocal leukoencephalopathy (PML).
  • Hepatotoxicity with jaundice.
  • Malignancies, particularly lymphoproliferative disorders.
  • Reproductive toxicity leading to fetal harm.

Precautions & Warnings

  • When prescribing Mycophenolate Mofetil, clinicians should consider several safety measures.
  • Monitor blood counts: regular CBC to detect cytopenias.
  • Assess renal function: dose may need adjustment in renal impairment.
  • Screen for infections: evaluate for latent TB and viral hepatitis before initiation.
  • Avoid live vaccines: patients on therapy have reduced immune defenses.
  • Pregnancy warning: drug is contraindicated in pregnancy due to teratogenic risk.
  • Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture.

Avoid Interactions

Mycophenolate Mofetil interacts with several medicines that can alter its exposure or increase toxicity.

Major Interactions (Avoid)

  • Antacids containing magnesium or aluminum: reduce absorption of the drug.
  • Azathioprine: additive bone‑marrow suppression.
  • Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): markedly lower mycophenolate levels.

Moderate Interactions (Monitor Closely)

  • ACE inhibitors or ARBs: may enhance renal effects.
  • Trimethoprim‑sulfamethoxazole: increased risk of myelosuppression.
  • Vaccines: live attenuated vaccines should be avoided during therapy.

Frequently Asked Questions

Micofenolato De Mofetil Aurovitas contains mycophenolate mofetil, an immunosuppressant used to prevent rejection after organ transplantation and to treat autoimmune diseases such as lupus nephritis by dampening the immune response.

Mycophenolate mofetil inhibits the enzyme inosine monophosphate dehydrogenase, blocking the synthesis of guanosine nucleotides. This limits the proliferation of T‑ and B‑lymphocytes, which are essential for mounting immune reactions, thereby reducing graft rejection and autoimmune inflammation.

The appropriate dose is determined by the prescribing clinician based on the patient’s condition, transplant type, renal function and other clinical factors. Dosage regimens are individualized and should follow the prescriber’s instructions.

Mycophenolate mofetil is classified as Pregnancy Category D because it can cause fetal harm. It is contraindicated in pregnancy and should be discontinued before conception. Breastfeeding is not recommended while taking this medication.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with calcineurin inhibitors such as cyclosporine or tacrolimus, mycophenolate mofetil offers a different mechanism—targeting nucleotide synthesis rather than calcineurin pathways. It is often used in combination regimens to provide synergistic immunosuppression while potentially reducing nephrotoxicity associated with calcineurin agents.

The product should be stored at ambient temperature, below 25 °C, in its original packaging to protect from moisture and light. Keep the container tightly closed and out of reach of children.

It is taken orally, usually as a tablet, with or without food as directed by the prescriber. The exact schedule (once or twice daily) and timing relative to meals are individualized based on therapeutic goals.

Serious risks include severe infections, opportunistic infections such as Pneumocystis jirovecii pneumonia, profound neutropenia or agranulocytosis, liver toxicity, and rare but potentially fatal malignancies. Patients should be monitored closely for signs of infection or abnormal blood counts.

The drug is contraindicated in patients with known hypersensitivity to mycophenolate mofetil, those who are pregnant, and individuals with severe, uncontrolled infections. Caution is also advised in patients with significant renal or hepatic impairment.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Mycophenolate Mofetil

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT